Simplifying detector modernization: Transferring a validated USP monograph method for deoxycholic acid across generations of charged aerosol detectors

Importance of the topic

Maintaining validated analytical methods during instrument upgrades is critical for regulated pharmaceutical laboratories. Compendial HPLC methods using charged aerosol detection (CAD) are particularly sensitive to detector-specific settings that affect response linearity and quantitation. Demonstrating reliable transfer of a USP monograph method across CAD generations safeguards method continuity, regulatory compliance, and data comparability while reducing downtime and revalidation effort.

Goals and overview of the study

This application study aimed to transfer the USP-NF HPLC-CAD monograph for deoxycholic acid (assay and organic impurities) from a Thermo Scientific Corona Veo RS Detector to a Thermo Scientific Vanquish Charged Aerosol Detector HP (CAD HP). The work verified system suitability, chromatographic comparability, and analytical performance after automated method translation using Chromeleon CDS. The goal was to show seamless modernization with minimal manual setup risk and equivalent analytical outcomes.

Methodology and experimental approach

Two sample types were prepared: USP reference standards for system suitability and calibration, and a commercial sample labeled for research use to assess assay and impurity profiling. Stock solutions were prepared at 1 mg/mL in 80/20 methanol/water and diluted to working concentrations per the USP procedure. Calibration points ranged down to 0.0005 mg/mL by serial dilution.

Chromatographic conditions (summary):

• Column: Thermo Scientific Acclaim 120 C18, 4.6 × 150 mm, 3 µm
• Mobile phases: 0.1% formic acid in water (A) and 0.1% formic acid in acetonitrile (B)
• Gradient: increasing organic content (start ≈25% B to 100% B within the runtime), total runtime ~38 min
• Flow rate: 1.0 mL/min; column temperature: 30 °C; autosampler: 6 °C; injection: 25 µL
• Needle wash: 80/20 water/methanol
• Detector settings after transfer: evaporation temperature 50 °C, data rate 20 Hz, filter 5 s, equivalent detector power-function linearization applied (PFV 1.2 → PV 1.8)

Instrumentation used

The study used Thermo Scientific systems and consumables, including:

• Vanquish Flex UHPLC System with Quaternary Pump F, Split Sampler FT, and Column Compartment H
• Vanquish Charged Aerosol Detector HP (target detector)
• Vanquish Flex system paired with a Corona Veo RS Detector (source device) for comparison
• Chromeleon 7.3.2 Chromatography Data System for acquisition, automated method translation, and data processing

Main results and discussion

Automated method translation and system suitability:

• Chromeleon CDS method-translation wizard converted detector-specific parameters (nomenclature, units, and power-function settings) in three user steps, producing a ready-to-run method on the Vanquish CAD HP without manual reconfiguration.
• System suitability on the Vanquish CAD HP met USP criteria: peak area RSD = 0.89% (requirement ≤3%) and S/N ≥ 40 (requirement ≥10).

Linearity and detector response:

• Both detector generations exhibited excellent linearity for deoxycholic acid with R² values of 0.99981 (Corona Veo RS) and 0.99985 (Vanquish CAD HP), confirming preservation of response linearization after conversion of the power-function parameter.

Chromatographic comparability and impurity profiling:

• Relative retention times (RRTs) for four known impurities and seven unknown impurities were identical between detectors, indicating preserved chromatographic behavior after transfer.
• The Vanquish CAD HP produced slightly higher absolute detector responses, reflected in modest differences in calculated impurity percentages (e.g., total unknown impurities 0.15% vs. 0.22% and total impurities 1.14% vs. 1.24%), but all total impurity results remained well below the USP acceptance limit of 2.0%.

Assay outcome for the commercial sample:

• Both systems determined the deoxycholic acid content well below the USP assay specification (97–103%): 81% (Corona Veo RS) and 79% (Vanquish CAD HP), confirming that the tested material labeled for research use is not suitable as a pharmaceutical-grade API.
• One known impurity (3α,12α-dihydroxy-5β-chol-9(11)-en-24-oic acid) exceeded the USP per-compound acceptance criterion (≤0.15%) on both systems (≈0.31–0.32%), reinforcing the conclusion of nonconformance.

Benefits and practical applications of the method transfer

The study demonstrates several practical advantages for QC and regulated laboratories:

• Automated method translation reduces manual transcription errors and accelerates detector modernization.
• Preserved system suitability and comparable analytical performance support regulatory continuity and reduce the need for extensive method redevelopment.
• Consistent impurity profiling and retention behavior facilitate routine release testing and stability investigations after instrument upgrades.

Future trends and possibilities for use

Key directions and opportunities emerging from this work:

• Broader adoption of automated method translation tools across CDS platforms to simplify transfers between instrument families and vendors.
• Standardization of detector parameter mapping (e.g., formalizing equivalence of power-function settings) to further reduce ambiguity during modernization.
• Expansion of transfer-validation case studies across diverse analyte classes and detector technologies to build regulatory confidence and establish best practices.
• Integration of automated translation with electronic change control and instrument qualification workflows to streamline documentation for regulated labs.

Conclusion

Transferring the USP monograph HPLC-CAD method for deoxycholic acid from a Corona Veo RS Detector to a Vanquish CAD HP was successful. Automated method translation via Chromeleon CDS enabled a straightforward conversion of detector-specific settings while preserving system suitability, linearity, and impurity profiling. Small, expected differences in absolute detector response did not affect the analytical conclusions: both systems identified the tested commercial material as failing USP assay criteria and reported comparable impurity patterns. The work supports confident detector modernization with minimal method rework in regulated pharmaceutical environments.

References

1. United States Pharmacopeia (USP) Deoxycholic Acid Monograph, USP 40–NF 35 – Assay and Organic Impurities, Official from August 1, 2017.
2. Thermo Fisher Scientific Technical Note 003816: Method transfer and optimization of deoxycholic acid analysis using HPLC-CAD, 2025.
3. Thermo Fisher Scientific Application Note 72600: Deoxycholic acid method transfer from the Corona ultra RS Charged Aerosol Detector to the Corona Veo (or Vanquish) Charged Aerosol Detector, 2018.